A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 584-587

  Weinberger, Andrea H ^a   Vessicchio, Jennifer C ^a   Sacco, Kristi A ^a   Creeden, Cerissa L ^a   Chengappa, K N Roy ^b,c   George, Tony P ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Mayview State Hospital   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; LITHIUM; VALPROIC ACID; ANTIDEPRESSANT AGENT;

ADULT; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE DURATION; FEMALE; HAMILTON SCALE; HUMAN; LETTER; MALE; ONSET AGE; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SMOKING CESSATION; SUSTAINED RELEASE FORMULATION; TOBACCO DEPENDENCE; YOUNG MANIA RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; BUPROPION; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SMOKING CESSATION;

EID: 58149123110     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318184ba3c     Document Type: Letter

References (17)

1. Lasser K, Boyd JW, Woolhander S, et al. Smoking and mental illness: a populationbased prevalence study. JAMA. 2000;284: 2606-2610.
2. Waxmonsky JA, Thomas MR, Miklowitz DJ, et al. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the systematic treatment enhancement program. Gen Hosp Psychiatry. 2005;27:321-328.
3. Ostacher MJ, Nierenberg AA, Perlis RH, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry. 2006;67:1907-1911.
4. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antide- pressant activity. J Clin Psychiatry. 1995;56: 395-401.
5. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
6. George TP, Vessicchio JC, Termine A, et al. A placebo-controlled study of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53-61.
7. George TP, Zeidonis DM, Feingold A, et al. Nicotine transdermal patch and atypical anti- psychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157: 1835-1842.
8. Sobell LC, Sobell MB, Leo GI, et al. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Brit J Addiction. 1988;83:393-102.
9. Young R, Biggs J, Meyer D. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;1978:429-435.
10. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100.
11. Hamilton M. A rating scale for depression. JNeurolNeurosurgPsychiatry. 1960;23:56-62.
12. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminarysingle-blind study. Bipolar Disord. 2002;4:207-213.
13. Goldberg JF, Truman CJ. Antidepressantinduced mania: an overview of current controversies. Bipolar Disord. 2003;5:407-420.
14. Joffe RT, MacQueen GM, Marriott M, et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand. 2002; 10:427-430.
15. Mundo E, Walker M, Cate T, et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry. 2001;58:539-544.
16. Rousseva A, Henry C, Van Den Bulke D, et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 2003;3: 101-104.
17. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 2005;25:226-229.